Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Medbanks
思 派 健 康 科 技

Sipai Health Technology Co., Ltd.
思派健康科技有限公司

(A company incorporated in the Cayman Islands with limited liability)
(Stock Code: 0314)

POSITIVE PROFIT ALERT – TURNAROUND FROM NET LOSS TO NET PROFIT

This announcement is made by Sipai Health Technology Co., Ltd. (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Director(s)**") of the Company wishes to inform the shareholders (the "**Shareholders**") and potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 (the "**Period**") and the information currently available to the Board, the Group expects that:

1) the Group will record a net profit for the Period ranging from RMB41.0 million to RMB44.0 million, as compared to a net loss of approximately RMB81.1 million for the corresponding period in 2025, representing a turnaround of approximately RMB122.1 million to RMB125.1 million.

2) the normalized net profit[1] of the Group for the Period will range from RMB6.0 million to RMB7.0 million, as compared to a normalized net loss of approximately RMB12.0 million for the corresponding period in 2025, representing an improvement of approximately RMB18.0 million to RMB19.0 million.

[1] The normalized net profit is calculated as net profit (based on the International Financial Reporting Standards (IFRSs)) deducting non-recurring and non-operational items that we believe do not reflect the ongoing operating performance. For the Period, such items mainly include (i) share-based payment compensation; (ii) restructuring cost; (iii) gain on disposal of subsidiaries; and (iv) non-recurring government grant.

To the best knowledge of the Board, the turnaround to profitability was mainly attributable to (i) the strong growth achieved by the Group's core businesses, namely the corporate insurance services business and the physician research assistance business; (ii) the improvement in the Group's gross profit margin as a result of the rising share of higher-margin core businesses; (iii) the reduction in selling and administrative expenses resulting from a series of quality-enhancement and efficiency-improvement initiatives; (iv) the gain on disposal of subsidiaries in the first half of 2026, while loss was incurred from a disposal of subsidiaries in 2025; and (v) the decrease in the share-based payment compensation.

The Company is still in the process of finalizing the interim results of the Group for the Period. The information contained in this announcement is only a preliminary assessment by the Board based on the figures and information currently available to the Board as at the date of this announcement, and is not audited or reviewed by the auditors and/or the audit committee of the Company and may differ from the actual interim results of the Group for the Period. Shareholders and potential investors of the Company should refer to and carefully read the interim results announcement of the Company for the Period, which is expected to be published in August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Sipai Health Technology Co., Ltd.
MA Xuguang
Chairman of the Board and Executive Director

Hong Kong, August 4, 2026

As at the date of this announcement, the Board comprises Mr. MA Xuguang and Mr. LI Ji as executive directors, Mr. YAO Leiwen as non-executive director, Mr. FAN Xin, Mr. HE Haijian and Ms. HUANG Bei as independent non-executive directors.